FXN and Friedreich ataxia: Our findings shed new light on the role of frataxin in the metabolic dysfunctions leading to FRDA and could pave the way to future therapeutic strategies in the disease treatment focused on respiratory complex I. Experiments are currently underway in our laboratory to obtain molecular details of the interaction between frataxin and complex I that could drive the design of peptidomimetics able to stabilize this complex in FRDA patients’ cells.